FDA approves new treatment for patients with migraine | FDA

The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.
— Read on www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine

Leave a Reply

Your email address will not be published. Required fields are marked *